BCM
BIIB icon

Bluefin Capital Management’s Biogen BIIB Stock Holding History

Bluefin Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-17,100
Closed -$3K – 343
2019
Q1 		$3K Buy
+17,100
New +$5.38M ﹤0.01% 377
2016
Q3 		– Sell
-11,200
Closed -$2K – 448
2016
Q2 		$2K Buy
+11,200
New +$2.95M ﹤0.01% 477

Other funds holding BIIB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bluefin Capital Management's BIIB Position: Q3 2016 in Review

Bluefin Capital Management sold out of Biogen (BIIB) in Q3 2016, closing a stake of 851 shares — an estimated $206K sold.

Bluefin Capital Management first reported a position in BIIB in Q1 2014 and held it in 2 quarters. The position peaked at $600K in Q1 2014. 1,012 funds tracked by Wall St. Rank hold BIIB as of Q3 2016.

  • Bluefin Capital Management reported no remaining Biogen position as of Q3 2016 after selling out during the quarter.
  • Bluefin Capital Management sold 851 Biogen shares in Q3 2016, an estimated $206K.
  • Bluefin Capital Management first reported a position in Biogen in Q1 2014 and held it in 2 quarters.
  • Bluefin Capital Management's Biogen position peaked at $600K in Q1 2014.
  • 1,012 funds tracked by Wall St. Rank held Biogen as of Q3 2016.

Based on Bluefin Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.